CD137 stimulation enhances the vaccinal effect of anti-tumor antibodies.

PubWeight™: 0.79‹?›

🔗 View Article (PMID 25610724)

Published in Oncoimmunology on July 03, 2014

Authors

Roch Houot1, Holbrook Kohrt2

Author Affiliations

1: CHU Rennes; Service Hématologie Clinique ; Rennes, France ; INSERM ; Rennes, France.
2: Department of Medicine, Division of Oncology; Stanford University ; Stanford, CA USA.

Associated clinical trials:

A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab | NCT01307267

Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma | NCT01775631